iRadimed/$IRMD
iRadimed shares fall after Q3 results, as Q4 revenue and adjusted EPS guidance came in below expectations and management lowered the upper end of its FY26 revenue and EPS outlook.
18 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About iRadimed
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
- Ticker
- $IRMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 166
- Headquarters
- Orlando, United States
- Website
- www.iradimed.com
iRadimed Metrics
BasicAdvanced
$981M
41.01
$1.87
-
$1.27
1.04%
Price and volume
Market cap
$981M
52-week high
$107.90
52-week low
$76.35
Average daily volume
124K
Dividend rate
$1.27
Financial strength
Current ratio
8.99
Quick ratio
6.131
Profitability
EBITDA (TTM)
30.47
Gross margin (TTM)
75.51%
Net profit margin (TTM)
26.85%
Operating margin (TTM)
32.30%
Effective tax rate (TTM)
22.92%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
15.30%
Return on equity (TTM)
23.42%
Valuation
Price to earnings (TTM)
41.01
Price to revenue (TTM)
10.962
Price to book
9.21
Price to tangible book (TTM)
9.21
Dividend yield (TTM)
1.66%
Forward dividend yield
1.04%
Growth
Revenue change (TTM)
10.97%
Earnings per share change (TTM)
13.33%
3-year revenue growth (CAGR)
12.36%
10-year revenue growth (CAGR)
9.84%
3-year earnings per share growth (CAGR)
13.17%
10-year earnings per share growth (CAGR)
10.67%
What the Analysts think about iRadimed
Analyst ratings (Buy, Hold, Sell) for iRadimed stock.
Analyst projections of the future price of iRadimed stock.
Bulls say / Bears say
The new 3870 launch is translating into sales: third-quarter revenue reached a record $24.2 million, up 14% year on year, while diluted earnings per share rose 17%. (GlobeNewswire)
The 3870 has a meaningful replacement opportunity: over 70% of pump bookings were for quad-stack systems, which double the channels available at each MRI compared with the older set-up. Record pump bookings suggest customers are moving to the higher-capacity configuration. (GlobeNewswire)
Growth is not limited to pumps: third-quarter monitor revenue rose 17%, disposables revenue rose 21%, and international revenue grew 45%, giving the company several sources of sales growth. (GlobeNewswire)
The production ramp is still constraining shipments: iRadimed cut the top of its 2026 revenue outlook from $96 million to $93.1 million. The CEO said the company would not push production so hard that product quality could slip. (GlobeNewswire, Benzinga)
Gross margin was 76% in the third quarter, still below 78% a year earlier as start-up inefficiencies from the 3870 continued. Further profit improvement depends on the company scaling production smoothly. (GlobeNewswire)
Valuation may leave limited room for setbacks: Needham initiated coverage with a Hold rating, citing valuation concerns, and Investing.com reported a price-to-earnings ratio of 46.21 and an EV-to-EBITDA ratio of 34.11. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
iRadimed Financial Performance
Revenues and expenses
iRadimed Earnings Performance
Company profitability
Upcoming events
iRadimed News
AllArticlesVideos
Funds containing iRadimed
Fund name | Fund size | $IRMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.